Acute myeloblastic leukemia achieving complete remission with Amifostine alone

dc.contributor.authorÖztürk, Ahmet Kutlu
dc.contributor.authorOrhan, Bülent
dc.contributor.authorTürken, Orhan
dc.contributor.authorEtiz, Durmuş
dc.contributor.authorYaylacı, Mustafa
dc.contributor.authorÜskent, Necdet
dc.date.accessioned2021-02-19T10:53:56Z
dc.date.available2021-02-19T10:53:56Z
dc.date.issued2002
dc.description.abstractAmifostine, a phosphorylated thiol-amine, is known as a cytoprotective agent especially for cisplatin containing chemotherapies. Apart from the cytoprotective role, Amifostine could also be used in the treatment of hematologic malignancies such as myelodysplastic syndrome (MDS) and acute myeloblastic leukemia (AML), as a treatment option or for potentiating the effects of cytotoxic agents. We tried to use Amifostine in a patient with AML, which did not respond to conventional cytotoxic chemotherapy and aimed to publish the results. The patient was a 77-year-old male patient, he was diagnosed as AML by peripheral blood smear and bone marrow aspiration. Treatment commenced with low dose cytosine arabinoside (Ara-C) but the therapy should have ceased due to patient intolerance. The patient refused further therapy and he was offered to have Amifostine treatment. Amifostine was administered 200 mg/m2 three times a week, with ciprofloxacin, pentoxifyllin and dexamethasone. Dramatic response was obtained after 8 weeks of administration. Blast rate was reduced from 35 to 7% in bone marrow aspiration; pancytopenia was restored to normal levels. This remission was maintained through 8 more weeks. Amifostine treatment was restarted after he relapsed but this time he did not respond to the treatment and died of gastrointestinal bleeding on the 8th week of treatment.en_US
dc.identifier.citation5
dc.identifier.doi10.1080/10428190290006341en_US
dc.identifier.endpage453en_US
dc.identifier.issn1042-8194en_US
dc.identifier.issn1042-8194
dc.identifier.issue2en_US
dc.identifier.pmid11999588en_US
dc.identifier.scopus2-s2.0-0036193050en_US
dc.identifier.scopusqualityN/A
dc.identifier.startpage451en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12469/3956
dc.identifier.volume43en_US
dc.identifier.wosqualityQ3
dc.institutionauthorÜskent, Necdeten_US
dc.language.isoenen_US
dc.relation.journalLeukemia and Lymphomaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute myeloblastic leukemiaen_US
dc.subjectAmifostine treatmenten_US
dc.subjectElderly patienten_US
dc.subjectMyelodysplastic syndromeen_US
dc.titleAcute myeloblastic leukemia achieving complete remission with Amifostine aloneen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files